Dianthus Therapeutics, Inc. (DNTH) Earnings Call Transcripts
Dianthus Therapeutics, Inc.'s Latest Earnings Call - June 9, 2026
In the second quarter of 2026, Dianthus Therapeutics (DNTH:US) reported significant advancements in its clinical pipeline, particularly with its lead asset, claseprubart, for treating neuromuscular conditions. The company raised a total of $1.007 billion in recent financing rounds, providing a strong cash position of $1.2 billion, which is expected to fund operations into 2030. Management maintained a positive outlook, emphasizing the upcoming Phase III trials for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with data readouts anticipated later this year.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | $1.2B (positive) |
| Total Capital Raised | $1.007B (positive) |
| Phase II Trial Size (MG) | 40 patients (positive) |
| Phase II Trial Size (CIDP) | 40 patients (positive) |
| Projected Market Size for MMN | $5B (positive) |
| Target Dose for claseprubart | 300 mg (positive) |
Guidance from management
Dianthus plans to initiate Phase III trials for MG and CIDP in mid-2026, with results anticipated in the second half of the year. The company is focused on executing trials efficiently to capitalize on its strong cash position.
What analysts pressed on
Analysts expressed concerns about the competitive landscape, particularly regarding the efficacy of claseprubart compared to existing treatments. There were also questions about the potential impact of the high placebo response observed in previous trials and how it might affect future data interpretation.
Main topics on the call
- Strong Cash Position — Dianthus has $1.2 billion in cash, which will support operations into 2030. CEO Marino Garcia stated, 'We have the cash, potentially try to do as many of the pivotal trials in parallel as quickly as possible.'
- Positive Clinical Data for claseprubart — The company reported strong efficacy data from Phase II trials in MG and CIDP, with Garcia noting, 'We had very strong statistically significant data.' This positions claseprubart favorably against competitors.
- Upcoming Phase III Trials — Management confirmed the initiation of Phase III trials for MG and CIDP, with results expected in the second half of 2026. Garcia highlighted, 'Everything is on track to get that study started.'
- Market Opportunity in MMN — Garcia emphasized the potential of the multifocal motor neuropathy (MMN) market, stating, 'This is a multibillion-dollar opportunity.' The company aims to capture market share with its potent C1s inhibitor.
Read the full Dianthus Therapeutics, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 6 calls on record spanning January 15, 2025 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 6 Dianthus Therapeutics, Inc. earnings call transcripts on record, spanning January 15, 2025 to June 9, 2026. Based on this history, Dianthus Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- DNTH
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 6
- First call
- January 15, 2025
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly
| Quarter | Date | |
|---|---|---|
| Company Conference Presentations | Jun 9, 2026 | Read transcript → |
| Special Calls | Mar 9, 2026 | Read transcript → |
| Company Conference Presentations | Feb 12, 2026 | Read transcript → |
| Company Conference Presentations | Jan 12, 2026 | Read transcript → |
| Special Calls | Sep 8, 2025 | Read transcript → |
| Company Conference Presentations | Jan 15, 2025 | Read transcript → |